77.50p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arecor Therapeutics
Its shares trade on LSE under the ticker AREC.L. It has been listed since 3 June 2021. In the fiscal year to 31 December 2025, it reported revenue of £1.7m and net income of £664,000. At that date it held total assets of £8.1m and shareholders' equity of £6.5m.
Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The company is headquartered in Saffron Walden, Essex. The company went IPO on 2021-06-03. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. The company also has Tetris Pharma portfolio.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Jun 2021
- Employees
- 51
Leadership
Pay as last reported
- Mr. Andrew RichardsNon-Executive Chairman of the Board£80,000
- Dr. Sarah HowellChief Executive Officer, Executive Director, since 2021£434,000
- Mr. David EllamChief Financial Officer, Executive Director, since 2024
- Mr. Simon OrmistonNon-Executive Director
- Dr. Sam FazeliIndependent Non-Executive Director£35,000
- Mr. Jeremy MorganIndependent Non-Executive Director£40,000
- Ms. Christine SodenIndependent Non-Executive Director£40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arestat technology enhances existing therapeutic products for better patient care.
- AT247 accelerates insulin absorption to manage blood glucose levels effectively.
- 51 full-time employees support the internal portfolio development efforts.
Weaknesses
- The company relies on partnerships to deliver formulations to market.
- AT278 targets high concentration insulin delivery via lower injection volume.
- Diabetes indications represent a specific segment of the portfolio focus.
Opportunities
- Collaborating with pharmaceutical companies expands the reach of Arestat formulations.
- Developing products for other indications beyond diabetes offers growth potential.
- Improving mealtimes management addresses difficult-to-manage patient needs effectively.
Threats
- Competitors in the biotechnology sector may develop superior insulin solutions.
- Regulatory hurdles could delay the approval of AT247 and AT278.
- Market acceptance of ultra-rapid acting insulin remains uncertain for investors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.